Interleukin-27 signaling promotes immunity against endogenously arising murine tumors

PLoS One. 2013;8(3):e57469. doi: 10.1371/journal.pone.0057469. Epub 2013 Mar 12.

Abstract

Interleukin-27 (IL-27) is a pleiotropic cytokine but its immunosuppressive effects predominate during many in vivo immunological challenges. Despite this, evidence from tumor cell line transfer models suggested that IL-27 could promote immune responses in the tumor context. However, the role of IL-27 in immunity against tumors that develop in situ and in tumor immunosurveillance remain undefined. In this study, we demonstrate that tumor development and growth are accelerated in IL-27 receptor α (Il27ra)-deficient mice. Enhanced tumor growth in both carcinogen-induced fibrosarcoma and oncogene-driven mammary carcinoma was associated with decreased interferon-γ production by CD4 and CD8 T cells and increased numbers of regulatory T-cells (Treg). This is the first study to show that IL-27 promotes protective immune responses against endogenous tumors, which is critical as the basis for future development of an IL-27 based therapeutic agent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / pathology
  • Immune Tolerance / genetics
  • Interferon-gamma / genetics
  • Interferon-gamma / immunology
  • Interleukins / genetics
  • Interleukins / immunology*
  • Male
  • Mice
  • Mice, Knockout
  • Neoplasms, Experimental / genetics
  • Neoplasms, Experimental / immunology*
  • Neoplasms, Experimental / pathology
  • Neoplasms, Experimental / therapy
  • Receptors, Cytokine / genetics
  • Receptors, Cytokine / immunology*
  • Receptors, Interleukin
  • Signal Transduction / genetics
  • Signal Transduction / immunology*
  • T-Lymphocytes, Regulatory / immunology*
  • T-Lymphocytes, Regulatory / pathology

Substances

  • Il27 protein, mouse
  • Il27ra protein, mouse
  • Interleukins
  • Receptors, Cytokine
  • Receptors, Interleukin
  • Interferon-gamma

Grants and funding

M.B. is the recipient of a Career Development Fellowship (APP1031277) from the National Health and Medical Research Council (http://www.nhmrc.gov.au/), Australia. This work was also supported by an Early Career Fellowship (M.B.; 08ECF110) from the Cancer Institute New South Wales (http://www.cancerinstitute.org.au/). A.S. is the recipient of an Early Career Fellowship from the National Breast Cancer Foundation Australia (http://www.nbcf.org.au/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.